Benitec Biopharma Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
Benitec Biopharma Inc. (BNTC) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $638.00 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-14.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-09-14
- Benitec Biopharma Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2026 was $638.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2026-06-30 | $638.00K 10-K · filed 2026-09-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |